nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CYP3A4—Imiquimod—skin cancer	0.161	0.292	CbGbCtD
Maraviroc—CYP3A4—Temozolomide—skin cancer	0.161	0.292	CbGbCtD
Maraviroc—CYP3A4—Vismodegib—skin cancer	0.112	0.202	CbGbCtD
Maraviroc—CYP3A4—Vemurafenib—skin cancer	0.0882	0.16	CbGbCtD
Maraviroc—CYP3A4—Docetaxel—skin cancer	0.0303	0.0548	CbGbCtD
Maraviroc—CCR5—connective tissue—skin cancer	0.00975	0.285	CbGeAlD
Maraviroc—CCR5—lymphoid tissue—skin cancer	0.00713	0.208	CbGeAlD
Maraviroc—CCR5—female reproductive system—skin cancer	0.00688	0.201	CbGeAlD
Maraviroc—CCR5—head—skin cancer	0.00575	0.168	CbGeAlD
Maraviroc—CCR5—lymph node—skin cancer	0.00402	0.118	CbGeAlD
Maraviroc—CCR5—Peptide GPCRs—MC1R—skin cancer	0.00307	0.133	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Other—SMO—skin cancer	0.00176	0.0759	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—MC1R—skin cancer	0.00144	0.0623	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00113	0.0488	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—PTCH2—skin cancer	0.00102	0.044	CbGpPWpGaD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000968	0.0418	CbGpPWpGaD
Maraviroc—CCR5—HIV Life Cycle—ERCC2—skin cancer	0.00078	0.0337	CbGpPWpGaD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000743	0.0321	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—MC1R—skin cancer	0.000737	0.0318	CbGpPWpGaD
Maraviroc—CYP3A4—female reproductive system—skin cancer	0.000694	0.0203	CbGeAlD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000636	0.0275	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—RHOU—skin cancer	0.000633	0.0273	CbGpPWpGaD
Maraviroc—CCR5—HIV Infection—ERCC2—skin cancer	0.000539	0.0233	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—SHH—skin cancer	0.000525	0.0227	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PTCH2—skin cancer	0.000523	0.0226	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—PTCH1—skin cancer	0.000498	0.0215	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—SMO—skin cancer	0.000498	0.0215	CbGpPWpGaD
Maraviroc—Infestation—Temozolomide—skin cancer	0.000492	0.00126	CcSEcCtD
Maraviroc—Depression—Temozolomide—skin cancer	0.000491	0.00126	CcSEcCtD
Maraviroc—Blood alkaline phosphatase increased—Docetaxel—skin cancer	0.000488	0.00125	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.000488	0.00125	CcSEcCtD
Maraviroc—Body temperature increased—Vemurafenib—skin cancer	0.000486	0.00124	CcSEcCtD
Maraviroc—Pharyngitis—Dactinomycin—skin cancer	0.000485	0.00124	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—PTGER4—skin cancer	0.000485	0.0209	CbGpPWpGaD
Maraviroc—Pancytopenia—Fluorouracil—skin cancer	0.000483	0.00124	CcSEcCtD
Maraviroc—Neuropathy peripheral—Temozolomide—skin cancer	0.000482	0.00123	CcSEcCtD
Maraviroc—Stomatitis—Temozolomide—skin cancer	0.00048	0.00123	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000477	0.00122	CcSEcCtD
Maraviroc—Deafness—Docetaxel—skin cancer	0.000475	0.00121	CcSEcCtD
Maraviroc—Insomnia—Imiquimod—skin cancer	0.000474	0.00121	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Fluorouracil—skin cancer	0.000473	0.00121	CcSEcCtD
Maraviroc—Hepatic failure—Docetaxel—skin cancer	0.000473	0.00121	CcSEcCtD
Maraviroc—Paraesthesia—Imiquimod—skin cancer	0.00047	0.0012	CcSEcCtD
Maraviroc—Hepatobiliary disease—Temozolomide—skin cancer	0.000466	0.00119	CcSEcCtD
Maraviroc—Alopecia—Bleomycin—skin cancer	0.000463	0.00118	CcSEcCtD
Maraviroc—Erythema multiforme—Dactinomycin—skin cancer	0.000462	0.00118	CcSEcCtD
Maraviroc—Sinusitis—Temozolomide—skin cancer	0.000462	0.00118	CcSEcCtD
Maraviroc—Pneumonia—Fluorouracil—skin cancer	0.000456	0.00117	CcSEcCtD
Maraviroc—Erythema—Bleomycin—skin cancer	0.000456	0.00117	CcSEcCtD
Maraviroc—Decreased appetite—Imiquimod—skin cancer	0.000455	0.00117	CcSEcCtD
Maraviroc—Infestation NOS—Fluorouracil—skin cancer	0.000454	0.00116	CcSEcCtD
Maraviroc—Infestation—Fluorouracil—skin cancer	0.000454	0.00116	CcSEcCtD
Maraviroc—Hypersensitivity—Vemurafenib—skin cancer	0.000453	0.00116	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Imiquimod—skin cancer	0.000452	0.00116	CcSEcCtD
Maraviroc—Fatigue—Imiquimod—skin cancer	0.000452	0.00116	CcSEcCtD
Maraviroc—Pain—Imiquimod—skin cancer	0.000448	0.00115	CcSEcCtD
Maraviroc—Acute coronary syndrome—Fluorouracil—skin cancer	0.000447	0.00114	CcSEcCtD
Maraviroc—Neuropathy peripheral—Fluorouracil—skin cancer	0.000445	0.00114	CcSEcCtD
Maraviroc—Myocardial infarction—Fluorouracil—skin cancer	0.000445	0.00114	CcSEcCtD
Maraviroc—Stomatitis—Fluorouracil—skin cancer	0.000442	0.00113	CcSEcCtD
Maraviroc—Conjunctivitis—Fluorouracil—skin cancer	0.000441	0.00113	CcSEcCtD
Maraviroc—Asthenia—Vemurafenib—skin cancer	0.000441	0.00113	CcSEcCtD
Maraviroc—Hallucination—Temozolomide—skin cancer	0.00044	0.00112	CcSEcCtD
Maraviroc—Pharyngitis—Temozolomide—skin cancer	0.000439	0.00112	CcSEcCtD
Maraviroc—Urinary tract disorder—Temozolomide—skin cancer	0.000436	0.00112	CcSEcCtD
Maraviroc—Pruritus—Vemurafenib—skin cancer	0.000435	0.00111	CcSEcCtD
Maraviroc—Connective tissue disorder—Temozolomide—skin cancer	0.000434	0.00111	CcSEcCtD
Maraviroc—Urethral disorder—Temozolomide—skin cancer	0.000433	0.00111	CcSEcCtD
Maraviroc—Alopecia—Dactinomycin—skin cancer	0.000432	0.0011	CcSEcCtD
Maraviroc—Gastrointestinal pain—Imiquimod—skin cancer	0.000428	0.0011	CcSEcCtD
Maraviroc—Sinusitis—Fluorouracil—skin cancer	0.000425	0.00109	CcSEcCtD
Maraviroc—Erythema—Dactinomycin—skin cancer	0.000425	0.00109	CcSEcCtD
Maraviroc—Agranulocytosis—Fluorouracil—skin cancer	0.000423	0.00108	CcSEcCtD
Maraviroc—Anaemia—Bleomycin—skin cancer	0.000421	0.00108	CcSEcCtD
Maraviroc—Diarrhoea—Vemurafenib—skin cancer	0.00042	0.00108	CcSEcCtD
Maraviroc—Erythema multiforme—Temozolomide—skin cancer	0.000418	0.00107	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—MC1R—skin cancer	0.000416	0.018	CbGpPWpGaD
Maraviroc—Body temperature increased—Imiquimod—skin cancer	0.000414	0.00106	CcSEcCtD
Maraviroc—Abdominal pain—Imiquimod—skin cancer	0.000414	0.00106	CcSEcCtD
Maraviroc—Eye disorder—Temozolomide—skin cancer	0.000413	0.00106	CcSEcCtD
Maraviroc—Cardiac disorder—Temozolomide—skin cancer	0.00041	0.00105	CcSEcCtD
Maraviroc—Leukopenia—Bleomycin—skin cancer	0.000408	0.00104	CcSEcCtD
Maraviroc—Rhinitis—Fluorouracil—skin cancer	0.000408	0.00104	CcSEcCtD
Maraviroc—Dizziness—Vemurafenib—skin cancer	0.000406	0.00104	CcSEcCtD
Maraviroc—Pharyngitis—Fluorouracil—skin cancer	0.000404	0.00103	CcSEcCtD
Maraviroc—Angiopathy—Temozolomide—skin cancer	0.000401	0.00103	CcSEcCtD
Maraviroc—Mediastinal disorder—Temozolomide—skin cancer	0.000398	0.00102	CcSEcCtD
Maraviroc—Cough—Bleomycin—skin cancer	0.000398	0.00102	CcSEcCtD
Maraviroc—Anaemia—Dactinomycin—skin cancer	0.000393	0.00101	CcSEcCtD
Maraviroc—Vomiting—Vemurafenib—skin cancer	0.000391	0.000999	CcSEcCtD
Maraviroc—Alopecia—Temozolomide—skin cancer	0.00039	0.000999	CcSEcCtD
Maraviroc—Myalgia—Bleomycin—skin cancer	0.000388	0.000993	CcSEcCtD
Maraviroc—Abdominal pain upper—Docetaxel—skin cancer	0.000388	0.000993	CcSEcCtD
Maraviroc—Orthostatic hypotension—Docetaxel—skin cancer	0.000388	0.000993	CcSEcCtD
Maraviroc—Rash—Vemurafenib—skin cancer	0.000387	0.000991	CcSEcCtD
Maraviroc—Mental disorder—Temozolomide—skin cancer	0.000387	0.000991	CcSEcCtD
Maraviroc—Dermatitis—Vemurafenib—skin cancer	0.000387	0.00099	CcSEcCtD
Maraviroc—Hypersensitivity—Imiquimod—skin cancer	0.000386	0.000988	CcSEcCtD
Maraviroc—Headache—Vemurafenib—skin cancer	0.000385	0.000985	CcSEcCtD
Maraviroc—Malnutrition—Temozolomide—skin cancer	0.000385	0.000984	CcSEcCtD
Maraviroc—Erythema—Temozolomide—skin cancer	0.000385	0.000984	CcSEcCtD
Maraviroc—Breast disorder—Docetaxel—skin cancer	0.000384	0.000982	CcSEcCtD
Maraviroc—Discomfort—Bleomycin—skin cancer	0.000384	0.000981	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000382	0.000979	CcSEcCtD
Maraviroc—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000382	0.000979	CcSEcCtD
Maraviroc—Leukopenia—Dactinomycin—skin cancer	0.000381	0.000974	CcSEcCtD
Maraviroc—Nasopharyngitis—Docetaxel—skin cancer	0.00038	0.000972	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—MC1R—skin cancer	0.000378	0.0163	CbGpPWpGaD
Maraviroc—Asthenia—Imiquimod—skin cancer	0.000376	0.000962	CcSEcCtD
Maraviroc—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000375	0.000959	CcSEcCtD
Maraviroc—Oedema—Bleomycin—skin cancer	0.000372	0.000952	CcSEcCtD
Maraviroc—Pruritus—Imiquimod—skin cancer	0.000371	0.000948	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—HRAS—skin cancer	0.00037	0.016	CbGpPWpGaD
Maraviroc—Infection—Bleomycin—skin cancer	0.00037	0.000946	CcSEcCtD
Maraviroc—Nausea—Vemurafenib—skin cancer	0.000365	0.000934	CcSEcCtD
Maraviroc—Myalgia—Dactinomycin—skin cancer	0.000362	0.000926	CcSEcCtD
Maraviroc—Bronchospasm—Docetaxel—skin cancer	0.000361	0.000924	CcSEcCtD
Maraviroc—Tremor—Temozolomide—skin cancer	0.00036	0.000922	CcSEcCtD
Maraviroc—Alopecia—Fluorouracil—skin cancer	0.00036	0.000921	CcSEcCtD
Maraviroc—Diarrhoea—Imiquimod—skin cancer	0.000358	0.000917	CcSEcCtD
Maraviroc—Discomfort—Dactinomycin—skin cancer	0.000358	0.000915	CcSEcCtD
Maraviroc—Angina pectoris—Docetaxel—skin cancer	0.000358	0.000915	CcSEcCtD
Maraviroc—Anaemia—Temozolomide—skin cancer	0.000356	0.00091	CcSEcCtD
Maraviroc—Anorexia—Bleomycin—skin cancer	0.000355	0.000908	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—IL6—skin cancer	0.000355	0.0153	CbGpPWpGaD
Maraviroc—Erythema—Fluorouracil—skin cancer	0.000354	0.000907	CcSEcCtD
Maraviroc—Pancytopenia—Docetaxel—skin cancer	0.000349	0.000892	CcSEcCtD
Maraviroc—Oedema—Dactinomycin—skin cancer	0.000347	0.000888	CcSEcCtD
Maraviroc—Dizziness—Imiquimod—skin cancer	0.000346	0.000886	CcSEcCtD
Maraviroc—Infection—Dactinomycin—skin cancer	0.000345	0.000882	CcSEcCtD
Maraviroc—Leukopenia—Temozolomide—skin cancer	0.000344	0.000881	CcSEcCtD
Maraviroc—Neutropenia—Docetaxel—skin cancer	0.000343	0.000878	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000339	0.000868	CcSEcCtD
Maraviroc—Cough—Temozolomide—skin cancer	0.000336	0.000859	CcSEcCtD
Maraviroc—CCR5—Disease—CSPG4—skin cancer	0.000334	0.0144	CbGpPWpGaD
Maraviroc—Paraesthesia—Bleomycin—skin cancer	0.000334	0.000855	CcSEcCtD
Maraviroc—Convulsion—Temozolomide—skin cancer	0.000333	0.000853	CcSEcCtD
Maraviroc—Vomiting—Imiquimod—skin cancer	0.000333	0.000852	CcSEcCtD
Maraviroc—Anorexia—Dactinomycin—skin cancer	0.000331	0.000847	CcSEcCtD
Maraviroc—Rash—Imiquimod—skin cancer	0.00033	0.000845	CcSEcCtD
Maraviroc—Dermatitis—Imiquimod—skin cancer	0.00033	0.000844	CcSEcCtD
Maraviroc—Pneumonia—Docetaxel—skin cancer	0.000329	0.000842	CcSEcCtD
Maraviroc—Headache—Imiquimod—skin cancer	0.000328	0.00084	CcSEcCtD
Maraviroc—Anaemia—Fluorouracil—skin cancer	0.000328	0.000838	CcSEcCtD
Maraviroc—Myalgia—Temozolomide—skin cancer	0.000327	0.000838	CcSEcCtD
Maraviroc—Infestation NOS—Docetaxel—skin cancer	0.000327	0.000838	CcSEcCtD
Maraviroc—Infestation—Docetaxel—skin cancer	0.000327	0.000838	CcSEcCtD
Maraviroc—Anxiety—Temozolomide—skin cancer	0.000326	0.000835	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000325	0.000832	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000325	0.00083	CcSEcCtD
Maraviroc—Discomfort—Temozolomide—skin cancer	0.000324	0.000828	CcSEcCtD
Maraviroc—Decreased appetite—Bleomycin—skin cancer	0.000324	0.000828	CcSEcCtD
Maraviroc—Acute coronary syndrome—Docetaxel—skin cancer	0.000323	0.000826	CcSEcCtD
Maraviroc—Renal failure—Docetaxel—skin cancer	0.000322	0.000823	CcSEcCtD
Maraviroc—Myocardial infarction—Docetaxel—skin cancer	0.000321	0.000821	CcSEcCtD
Maraviroc—Neuropathy peripheral—Docetaxel—skin cancer	0.000321	0.000821	CcSEcCtD
Maraviroc—Stomatitis—Docetaxel—skin cancer	0.000319	0.000816	CcSEcCtD
Maraviroc—Jaundice—Docetaxel—skin cancer	0.000319	0.000816	CcSEcCtD
Maraviroc—Pain—Bleomycin—skin cancer	0.000318	0.000814	CcSEcCtD
Maraviroc—Conjunctivitis—Docetaxel—skin cancer	0.000318	0.000814	CcSEcCtD
Maraviroc—Leukopenia—Fluorouracil—skin cancer	0.000317	0.000812	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000316	0.000809	CcSEcCtD
Maraviroc—Oedema—Temozolomide—skin cancer	0.000314	0.000803	CcSEcCtD
Maraviroc—Infection—Temozolomide—skin cancer	0.000312	0.000798	CcSEcCtD
Maraviroc—Nausea—Imiquimod—skin cancer	0.000311	0.000796	CcSEcCtD
Maraviroc—Hepatobiliary disease—Docetaxel—skin cancer	0.00031	0.000792	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PTCH2—skin cancer	0.000309	0.0133	CbGpPWpGaD
Maraviroc—Nervous system disorder—Temozolomide—skin cancer	0.000308	0.000788	CcSEcCtD
Maraviroc—Convulsion—Fluorouracil—skin cancer	0.000307	0.000786	CcSEcCtD
Maraviroc—Agranulocytosis—Docetaxel—skin cancer	0.000305	0.000782	CcSEcCtD
Maraviroc—Skin disorder—Temozolomide—skin cancer	0.000305	0.00078	CcSEcCtD
Maraviroc—Myalgia—Fluorouracil—skin cancer	0.000302	0.000772	CcSEcCtD
Maraviroc—Decreased appetite—Dactinomycin—skin cancer	0.000302	0.000772	CcSEcCtD
Maraviroc—Fatigue—Dactinomycin—skin cancer	0.000299	0.000766	CcSEcCtD
Maraviroc—Anorexia—Temozolomide—skin cancer	0.000299	0.000766	CcSEcCtD
Maraviroc—Discomfort—Fluorouracil—skin cancer	0.000298	0.000763	CcSEcCtD
Maraviroc—Pain—Dactinomycin—skin cancer	0.000297	0.000759	CcSEcCtD
Maraviroc—Rhinitis—Docetaxel—skin cancer	0.000295	0.000754	CcSEcCtD
Maraviroc—Body temperature increased—Bleomycin—skin cancer	0.000294	0.000753	CcSEcCtD
Maraviroc—Pharyngitis—Docetaxel—skin cancer	0.000292	0.000746	CcSEcCtD
Maraviroc—Urinary tract disorder—Docetaxel—skin cancer	0.00029	0.000743	CcSEcCtD
Maraviroc—Oedema—Fluorouracil—skin cancer	0.000289	0.00074	CcSEcCtD
Maraviroc—Connective tissue disorder—Docetaxel—skin cancer	0.000289	0.000739	CcSEcCtD
Maraviroc—Urethral disorder—Docetaxel—skin cancer	0.000288	0.000737	CcSEcCtD
Maraviroc—Infection—Fluorouracil—skin cancer	0.000287	0.000735	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000286	0.000732	CcSEcCtD
Maraviroc—Insomnia—Temozolomide—skin cancer	0.000284	0.000727	CcSEcCtD
Maraviroc—Gastrointestinal pain—Dactinomycin—skin cancer	0.000284	0.000726	CcSEcCtD
Maraviroc—Nervous system disorder—Fluorouracil—skin cancer	0.000284	0.000726	CcSEcCtD
Maraviroc—Paraesthesia—Temozolomide—skin cancer	0.000282	0.000721	CcSEcCtD
Maraviroc—Erythema multiforme—Docetaxel—skin cancer	0.000278	0.000711	CcSEcCtD
Maraviroc—Anorexia—Fluorouracil—skin cancer	0.000276	0.000705	CcSEcCtD
Maraviroc—Eye disorder—Docetaxel—skin cancer	0.000275	0.000703	CcSEcCtD
Maraviroc—Abdominal pain—Dactinomycin—skin cancer	0.000274	0.000702	CcSEcCtD
Maraviroc—Body temperature increased—Dactinomycin—skin cancer	0.000274	0.000702	CcSEcCtD
Maraviroc—Hypersensitivity—Bleomycin—skin cancer	0.000274	0.000702	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—PTGER4—skin cancer	0.000274	0.0118	CbGpPWpGaD
Maraviroc—Decreased appetite—Temozolomide—skin cancer	0.000273	0.000698	CcSEcCtD
Maraviroc—Cardiac disorder—Docetaxel—skin cancer	0.000273	0.000698	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Temozolomide—skin cancer	0.000271	0.000693	CcSEcCtD
Maraviroc—Fatigue—Temozolomide—skin cancer	0.000271	0.000693	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—SHH—skin cancer	0.000269	0.0116	CbGpPWpGaD
Maraviroc—Constipation—Temozolomide—skin cancer	0.000268	0.000687	CcSEcCtD
Maraviroc—Pain—Temozolomide—skin cancer	0.000268	0.000687	CcSEcCtD
Maraviroc—Asthenia—Bleomycin—skin cancer	0.000267	0.000683	CcSEcCtD
Maraviroc—Angiopathy—Docetaxel—skin cancer	0.000267	0.000682	CcSEcCtD
Maraviroc—Mediastinal disorder—Docetaxel—skin cancer	0.000265	0.000678	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000264	0.000674	CcSEcCtD
Maraviroc—Pruritus—Bleomycin—skin cancer	0.000263	0.000674	CcSEcCtD
Maraviroc—Insomnia—Fluorouracil—skin cancer	0.000262	0.000669	CcSEcCtD
Maraviroc—Paraesthesia—Fluorouracil—skin cancer	0.00026	0.000665	CcSEcCtD
Maraviroc—Alopecia—Docetaxel—skin cancer	0.00026	0.000664	CcSEcCtD
Maraviroc—Mental disorder—Docetaxel—skin cancer	0.000257	0.000659	CcSEcCtD
Maraviroc—Gastrointestinal pain—Temozolomide—skin cancer	0.000257	0.000657	CcSEcCtD
Maraviroc—Erythema—Docetaxel—skin cancer	0.000256	0.000655	CcSEcCtD
Maraviroc—Malnutrition—Docetaxel—skin cancer	0.000256	0.000655	CcSEcCtD
Maraviroc—Hypersensitivity—Dactinomycin—skin cancer	0.000256	0.000654	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—SMO—skin cancer	0.000255	0.011	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PTCH1—skin cancer	0.000255	0.011	CbGpPWpGaD
Maraviroc—Decreased appetite—Fluorouracil—skin cancer	0.000251	0.000643	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00025	0.000639	CcSEcCtD
Maraviroc—Asthenia—Dactinomycin—skin cancer	0.000249	0.000637	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—PTGER4—skin cancer	0.000249	0.0107	CbGpPWpGaD
Maraviroc—Abdominal pain—Temozolomide—skin cancer	0.000248	0.000635	CcSEcCtD
Maraviroc—Body temperature increased—Temozolomide—skin cancer	0.000248	0.000635	CcSEcCtD
Maraviroc—Pain—Fluorouracil—skin cancer	0.000247	0.000633	CcSEcCtD
Maraviroc—Diarrhoea—Dactinomycin—skin cancer	0.000237	0.000608	CcSEcCtD
Maraviroc—Vomiting—Bleomycin—skin cancer	0.000237	0.000605	CcSEcCtD
Maraviroc—Anaemia—Docetaxel—skin cancer	0.000236	0.000605	CcSEcCtD
Maraviroc—Rash—Bleomycin—skin cancer	0.000235	0.0006	CcSEcCtD
Maraviroc—Dermatitis—Bleomycin—skin cancer	0.000234	0.0006	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—GLI2—skin cancer	0.000234	0.0101	CbGpPWpGaD
Maraviroc—Hypersensitivity—Temozolomide—skin cancer	0.000231	0.000592	CcSEcCtD
Maraviroc—Syncope—Docetaxel—skin cancer	0.000229	0.000587	CcSEcCtD
Maraviroc—Leukopenia—Docetaxel—skin cancer	0.000229	0.000586	CcSEcCtD
Maraviroc—Body temperature increased—Fluorouracil—skin cancer	0.000229	0.000585	CcSEcCtD
Maraviroc—CCR5—Disease—ENO2—skin cancer	0.000227	0.00982	CbGpPWpGaD
Maraviroc—CCR5—Disease—SHH—skin cancer	0.000227	0.00982	CbGpPWpGaD
Maraviroc—Asthenia—Temozolomide—skin cancer	0.000225	0.000576	CcSEcCtD
Maraviroc—Loss of consciousness—Docetaxel—skin cancer	0.000225	0.000575	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MC1R—skin cancer	0.000223	0.00965	CbGpPWpGaD
Maraviroc—Cough—Docetaxel—skin cancer	0.000223	0.000571	CcSEcCtD
Maraviroc—Pruritus—Temozolomide—skin cancer	0.000222	0.000568	CcSEcCtD
Maraviroc—Convulsion—Docetaxel—skin cancer	0.000222	0.000567	CcSEcCtD
Maraviroc—Nausea—Bleomycin—skin cancer	0.000221	0.000566	CcSEcCtD
Maraviroc—Vomiting—Dactinomycin—skin cancer	0.000221	0.000565	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—GLI1—skin cancer	0.00022	0.00951	CbGpPWpGaD
Maraviroc—Rash—Dactinomycin—skin cancer	0.000219	0.00056	CcSEcCtD
Maraviroc—Myalgia—Docetaxel—skin cancer	0.000218	0.000557	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000216	0.000553	CcSEcCtD
Maraviroc—Diarrhoea—Temozolomide—skin cancer	0.000215	0.00055	CcSEcCtD
Maraviroc—Hypersensitivity—Fluorouracil—skin cancer	0.000213	0.000545	CcSEcCtD
Maraviroc—Oedema—Docetaxel—skin cancer	0.000209	0.000534	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—SUFU—skin cancer	0.000209	0.00902	CbGpPWpGaD
Maraviroc—Dizziness—Temozolomide—skin cancer	0.000208	0.000531	CcSEcCtD
Maraviroc—Infection—Docetaxel—skin cancer	0.000207	0.000531	CcSEcCtD
Maraviroc—Nausea—Dactinomycin—skin cancer	0.000206	0.000528	CcSEcCtD
Maraviroc—Shock—Docetaxel—skin cancer	0.000205	0.000526	CcSEcCtD
Maraviroc—Nervous system disorder—Docetaxel—skin cancer	0.000205	0.000524	CcSEcCtD
Maraviroc—Pruritus—Fluorouracil—skin cancer	0.000205	0.000524	CcSEcCtD
Maraviroc—Skin disorder—Docetaxel—skin cancer	0.000203	0.000519	CcSEcCtD
Maraviroc—Vomiting—Temozolomide—skin cancer	0.0002	0.000511	CcSEcCtD
Maraviroc—Anorexia—Docetaxel—skin cancer	0.000199	0.000509	CcSEcCtD
Maraviroc—Rash—Temozolomide—skin cancer	0.000198	0.000506	CcSEcCtD
Maraviroc—Diarrhoea—Fluorouracil—skin cancer	0.000198	0.000506	CcSEcCtD
Maraviroc—Dermatitis—Temozolomide—skin cancer	0.000198	0.000506	CcSEcCtD
Maraviroc—Headache—Temozolomide—skin cancer	0.000197	0.000503	CcSEcCtD
Maraviroc—Dizziness—Fluorouracil—skin cancer	0.000191	0.000489	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00019	0.000487	CcSEcCtD
Maraviroc—Insomnia—Docetaxel—skin cancer	0.000189	0.000483	CcSEcCtD
Maraviroc—Paraesthesia—Docetaxel—skin cancer	0.000187	0.00048	CcSEcCtD
Maraviroc—Nausea—Temozolomide—skin cancer	0.000186	0.000477	CcSEcCtD
Maraviroc—CCR5—Disease—FOXO4—skin cancer	0.000185	0.008	CbGpPWpGaD
Maraviroc—Vomiting—Fluorouracil—skin cancer	0.000184	0.000471	CcSEcCtD
Maraviroc—Rash—Fluorouracil—skin cancer	0.000182	0.000467	CcSEcCtD
Maraviroc—Dermatitis—Fluorouracil—skin cancer	0.000182	0.000466	CcSEcCtD
Maraviroc—Decreased appetite—Docetaxel—skin cancer	0.000181	0.000464	CcSEcCtD
Maraviroc—Headache—Fluorouracil—skin cancer	0.000181	0.000464	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Docetaxel—skin cancer	0.00018	0.000461	CcSEcCtD
Maraviroc—Fatigue—Docetaxel—skin cancer	0.00018	0.000461	CcSEcCtD
Maraviroc—Constipation—Docetaxel—skin cancer	0.000179	0.000457	CcSEcCtD
Maraviroc—Pain—Docetaxel—skin cancer	0.000179	0.000457	CcSEcCtD
Maraviroc—Nausea—Fluorouracil—skin cancer	0.000172	0.00044	CcSEcCtD
Maraviroc—Gastrointestinal pain—Docetaxel—skin cancer	0.000171	0.000437	CcSEcCtD
Maraviroc—Body temperature increased—Docetaxel—skin cancer	0.000165	0.000422	CcSEcCtD
Maraviroc—Abdominal pain—Docetaxel—skin cancer	0.000165	0.000422	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—SHH—skin cancer	0.000159	0.00688	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—RASA1—skin cancer	0.000158	0.00683	CbGpPWpGaD
Maraviroc—Hypersensitivity—Docetaxel—skin cancer	0.000154	0.000394	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PTCH1—skin cancer	0.000151	0.00652	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SMO—skin cancer	0.000151	0.00652	CbGpPWpGaD
Maraviroc—Asthenia—Docetaxel—skin cancer	0.00015	0.000383	CcSEcCtD
Maraviroc—Pruritus—Docetaxel—skin cancer	0.000148	0.000378	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PTGER4—skin cancer	0.000147	0.00635	CbGpPWpGaD
Maraviroc—Diarrhoea—Docetaxel—skin cancer	0.000143	0.000365	CcSEcCtD
Maraviroc—Dizziness—Docetaxel—skin cancer	0.000138	0.000353	CcSEcCtD
Maraviroc—Vomiting—Docetaxel—skin cancer	0.000133	0.00034	CcSEcCtD
Maraviroc—CCR5—Disease—ERCC2—skin cancer	0.000132	0.0057	CbGpPWpGaD
Maraviroc—Rash—Docetaxel—skin cancer	0.000132	0.000337	CcSEcCtD
Maraviroc—Dermatitis—Docetaxel—skin cancer	0.000132	0.000336	CcSEcCtD
Maraviroc—Headache—Docetaxel—skin cancer	0.000131	0.000335	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—FOXO4—skin cancer	0.00013	0.00561	CbGpPWpGaD
Maraviroc—Nausea—Docetaxel—skin cancer	0.000124	0.000317	CcSEcCtD
Maraviroc—CCR5—Disease—TERT—skin cancer	0.000124	0.00535	CbGpPWpGaD
Maraviroc—CCR5—Disease—BRAF—skin cancer	9.8e-05	0.00423	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TERT—skin cancer	8.67e-05	0.00374	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTGS2—skin cancer	7.92e-05	0.00342	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—NRAS—skin cancer	7.3e-05	0.00315	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—BRAF—skin cancer	6.86e-05	0.00296	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—KRAS—skin cancer	6.28e-05	0.00271	CbGpPWpGaD
Maraviroc—CCR5—Disease—NRAS—skin cancer	6.16e-05	0.00266	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—HRAS—skin cancer	5.34e-05	0.00231	CbGpPWpGaD
Maraviroc—CCR5—Disease—KRAS—skin cancer	5.3e-05	0.00229	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL6—skin cancer	5.11e-05	0.00221	CbGpPWpGaD
Maraviroc—CCR5—Disease—HRAS—skin cancer	4.51e-05	0.00195	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NRAS—skin cancer	4.31e-05	0.00186	CbGpPWpGaD
Maraviroc—CCR5—Disease—IL6—skin cancer	4.31e-05	0.00186	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KRAS—skin cancer	3.71e-05	0.0016	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TP53—skin cancer	3.3e-05	0.00143	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HRAS—skin cancer	3.16e-05	0.00136	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL6—skin cancer	3.02e-05	0.0013	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PLIN2—skin cancer	2.59e-05	0.00112	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CSPG4—skin cancer	2.09e-05	0.000902	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ENO2—skin cancer	1.42e-05	0.000613	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ERCC2—skin cancer	8.24e-06	0.000356	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS2—skin cancer	4.94e-06	0.000213	CbGpPWpGaD
